**Introduction**

Gastroparesis is a condition in which the normal movement of food from the stomach to the small intestine is drastically slowed or has stopped. This can lead to nausea and vomiting. Gastric electrical stimulation (GES) is a treatment that sends weak electrical signals to the nerves and smooth muscles in the lower stomach. This treatment helps decrease nausea and vomiting caused by gastroparesis. A small battery-powered device is surgically placed in the skin in the lower belly area. Wires are then placed in the area to be stimulated. This policy discusses when GES may be considered medically necessary. It has also been proposed as a treatment for obesity. The one published medical study that looked at using GES for obesity did not show it improved weight loss. GES for obesity is considered investigational (unproven) because more medical studies are needed.

**Note:** The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.
**Service** | **Medical Necessity**
--- | ---
**Gastric electrical stimulation** | Gastric electrical stimulation may be considered medically necessary in the treatment of chronic, intractable nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology when ALL of the following criteria are met:
- Significantly delayed gastric emptying as documented by standard scintigraphic imaging of solid food
**AND**
- Patient is refractory or intolerant of prokinetic medications and antiemetic medications
**AND**
- Patient’s nutritional status is sufficiently low that total parenteral nutrition is likely to become medically necessary

Gastric electrical stimulation is investigational for the treatment of obesity and all other indications.

**Documentation Requirements**

The medical records submitted for review should document that medical necessity criteria are met. The record should include clinical documentation of ALL of the following:
- Member has chronic, intractable nausea and vomiting secondary to gastroparesis (inability to empty food) caused by diabetes or for an unknown reason
- Significantly delayed gastric emptying confirmed by standard scintigraphic imaging (gastric emptying scan) of solid food
- Member has not responded or is intolerant to the use of prokinetic (antireflux) and antiemetic (antinausea and vomiting) medications
- The need for parenteral nutrition is likely to become medically necessary because of member’s inadequate nutritional status

**Note:** Vagus nerve stimulation is addressed in a separate medical policy. See Related Policies.
## Coding

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CPT</strong></td>
<td></td>
</tr>
<tr>
<td>43647</td>
<td>Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum</td>
</tr>
<tr>
<td>43648</td>
<td>Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum</td>
</tr>
<tr>
<td>43881</td>
<td>Implantation or replacement of gastric neurostimulator electrodes, antrum, open</td>
</tr>
<tr>
<td>43882</td>
<td>Revision or removal of gastric neurostimulator electrodes, antrum, open</td>
</tr>
<tr>
<td><strong>HCPCS</strong></td>
<td></td>
</tr>
<tr>
<td>E0765</td>
<td>FDA approved nerve stimulator, with replaceable batteries, for treatment of nausea and vomiting</td>
</tr>
<tr>
<td>L8680</td>
<td>Implantable neurostimulator electrode, each</td>
</tr>
<tr>
<td>L8685</td>
<td>Implantable neurostimulator pulse generator, single array, rechargeable, includes extension</td>
</tr>
<tr>
<td>L8686</td>
<td>Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension</td>
</tr>
<tr>
<td>L8687</td>
<td>Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension</td>
</tr>
<tr>
<td>L8688</td>
<td>Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension</td>
</tr>
</tbody>
</table>

**Note:** CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

## Related Information

N/A

## Evidence Review
Description

Gastric electrical stimulation (GES) is performed using an implantable device designed to treat chronic drug-refractory nausea and vomiting secondary to gastroparesis of diabetic, postsurgical or idiopathic etiology. The device may be referred to as a gastric pacemaker.

Background

Gastric electrical stimulation (GES, also referred to as gastric pacing) has been investigated primarily as a treatment for gastroparesis. Currently available devices consist of a pulse generator which can be programmed to provide electrical stimulation at different frequencies. The pulse generator is connected to intramuscular stomach leads, which are implanted during laparoscopy or open laparotomy (see Regulatory Status section).

Gastroparesis is a chronic disorder of gastric motility characterized by delayed emptying of a solid meal from the stomach. Symptoms include bloating, distension, nausea, and vomiting. When severe and chronic, gastroparesis can be associated with dehydration, poor nutritional status, and poor glycemic control in diabetics. While most commonly associated with diabetes, gastroparesis is also found in chronic pseudo-obstruction, connective tissue disorders, Parkinson disease, and psychological pathologic conditions. Some cases may not be associated with an identifiable cause, and are referred to as idiopathic gastroparesis. Treatment of gastroparesis includes prokinetic agents such as cisapride and metoclopramide, and antiemetic agents such as metoclopramide, granisetron, or ondansetron. Severe cases may require enteral or total parenteral nutrition.

GES has also been investigated as a treatment of obesity. It is used to increase a feeling of satiety with subsequent reduction in food intake and weight loss. The exact mechanisms resulting in changes in eating behavior are uncertain but may be related to neurohormonal modulation and/or stomach muscle stimulation.

Summary of Evidence

For individuals who have gastroparesis who receive gastric electrical stimulation (GES), the evidence includes randomized controlled trials (RCTs) and systematic reviews. Relevant outcomes are symptoms and treatment-related morbidity. Five crossover RCTs have been
published. A 2017 meta-analysis of these 5 RCTs did not find a significant benefit of GES on the severity of symptoms associated with gastroparesis. Patients generally reported improved symptoms at follow-up whether or not the device was turned on, suggesting a placebo effect. The evidence is insufficient to determine the effects of the technology on health outcomes.

A Hayes Medical Technology Directory report analyzed the evidence (n=10 studies) for GES for the treatment of gastroparesis. The report evaluated controlled studies (n=7 studies/18-241 patients) and uncontrolled studies (n=3 studies/131-233 patients). The controlled trials included RCTs (n=3 studies), prospective (n=2), and retrospective studies (n=2). Patients were selected who had symptomatic gastroparesis refractory to medical treatment with diagnoses of diabetic gastric neuropathy or idiopathic gastroparesis. Exclusion criteria included the structural cause of symptoms, psychogenic vomiting, chemical dependency, previous gastric surgery, and pregnancy. Outcomes measured were gastroparesis symptom severity and gastric retention assessed by scintigraphy. Additional outcomes included the need for nutritional support, and changes in antiemetic and/or prokinetic medications. Follow-up timeframe varied among studies, the longest follow-up being four years. The report found poor to fair quality evidence indicating that GES may improve gastroparesis symptoms and gastric emptying as well as decrease the need for nutritional support in some patients with refractory gastroparesis. Overall, GES was found to be safe with the device removal rate ranging from 7%-12% in most studies, primarily due to lack of symptom improvement. It was noted that despite the low quality of the supportive evidence, GES may be an option for patients with debilitating gastroparesis that is refractory to medical treatment (Hayes, 2016 update).

Overall, the evidence for gastric electrical stimulation is not very strong. However, this Premera policy requires that the patient has tried and failed other treatments and that their nutritional status is so depleted that total parenteral nutrition (TPN) may soon become medically necessary. TPN is invasive and not without its own risks. Therefore, even though the evidence for gastric electrical stimulation is not strong and the Enterra Therapy System had only been approved by the FDA under a Humanitarian Device Exemption (HDE), GES may be helpful and allow the patient to avoid the risks associated with receiving ongoing TPN.

For individuals who have obesity who receive GES, the evidence includes 1 published RCT. Relevant outcomes are change in disease status and treatment-related morbidity. The SHAPE trial did not show significant improvement in weight loss with GES compared to sham stimulation. The evidence is insufficient to determine the effects of the technology on health outcomes.
Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02202434</td>
<td>Dermatome Electrical Stimulation on Individuals With Overweight and Class I Obesity</td>
<td>16</td>
<td>Mar 2018</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

* Denotes industry-sponsored or cosponsored trial.

Clinical Input Received from Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may provide appropriate reviewers who collaborate with and make recommendations during this process, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2015 Input

In response to requests, input was received from 1 specialty society (2 reviewers) and 4 academic centers while this policy was under review in 2015. Most respondents agreed that gastric electrical stimulation (GES) should be considered investigational for gastroparesis. There was a lack of consensus whether GES should be considered medically necessary for any specific indication (eg, diabetic gastroparesis, idiopathic gastroparesis, gastroparesis of postsurgical etiology). The reviewers were not asked about GES for treatment of obesity.
**2009 Input**

In response to requests, input was received from 4 academic medical centers (5 reviewers) while this policy was under review in 2009. There was strong agreement among reviewers about the limited data for use of GES in diabetic and idiopathic gastroparesis and about the need for randomized controlled trials. There was strong agreement that GES is investigational in the treatment of obesity.

**Practice Guidelines and Position Statements**

*National Institute for Health and Care Excellence*

In 2014, the National Institute for Health and Care Excellence (NICE) issued guidance on gastroelectrical stimulation for gastroparesis. NICE made the following recommendations\(^\text{15}\):

1. “Current evidence on the efficacy and safety of gastric electrical stimulation for gastroparesis is adequate to support the use of this procedure with normal arrangements for clinical governance, consent, and audit.

2. During the consent process, clinicians should inform patients considering gastric electrical stimulation for gastroparesis that some patients do not get any benefit from it. They should also give patients detailed written information about the risk of complications, which can be serious, including the need to remove the device.

3. Patient selection and follow-up should be done in specialist gastroenterology units with expertise in gastrointestinal motility disorders, and the procedure should only be performed by surgeons working in these units.”

*American College of Gastroenterology*

The American College of Gastroenterology (ACG) published clinical practice guidelines on management of gastroparesis in 2013.\(^\text{16}\) ACG recommended that:

GES [gastric electrical stimulation] may be considered for compassionate treatment in patients with refractory symptoms, particularly nausea and vomiting. Symptom severity and gastric emptying have been shown to improve in patients with DG [diabetic gastroparesis], but not in patients with IG [idiopathic gastroparesis] or PSG [postsurgical gastroparesis]. [Conditional recommendation (there is uncertainty about trade-offs), moderate level of
evidence (further research would be likely to have an impact on the confidence in the estimate of effect).

Medicare National Coverage

There is no national coverage determination (NCD). In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Regulatory Status

In 2000, the Gastric Electrical Stimulator (GES) system (now called Enterra™ Therapy System; Medtronic, Minneapolis, MN) was approved by the U.S. Food and Drug Administration (FDA) through the humanitarian device exemption process (HDE Approval H990014) for the treatment of gastroparesis. The GES system consists of 4 components: the implanted pulse generator, 2 unipolar intramuscular stomach leads, the stimulator programmer, and the memory cartridge. With the exception of the intramuscular leads, all other components have been used in other implantable neurologic stimulators, such as spinal cord or sacral nerve stimulation. The intramuscular stomach leads are implanted either laparoscopically or during a laparotomy and are connected to the pulse generator, which is implanted in a subcutaneous pocket. The programmer sets the stimulation parameters, which are typically set at an “on” time of 0.1 second alternating with an “off” time of 5.0 seconds.

Currently, no GES devices have been approved by FDA for the treatment of obesity. The Transcend® (Transneuronix; acquired by Medtronic in 2005), an implantable gastric stimulation device, is available in Europe for treatment of obesity.

References


History

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/18/01</td>
<td>Add to Surgery Section - New Policy</td>
</tr>
<tr>
<td>03/11/03</td>
<td>Replace Policy - 2002 updates added; policy statement unchanged.</td>
</tr>
<tr>
<td>05/11/04</td>
<td>Replace Policy - Policy revised; no change in policy statement; new HCPC code added.</td>
</tr>
<tr>
<td>06/08/04</td>
<td>Replace Policy - Policy replaces BC.7.01.73 due to policy statement being changed from investigational to medically necessary.</td>
</tr>
<tr>
<td>Date</td>
<td>Comments</td>
</tr>
<tr>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>09/01/04</td>
<td>Replace Policy - Policy renumbered from PR.7.01.122. No changes to dates.</td>
</tr>
<tr>
<td>01/11/05</td>
<td>Replace Policy - BCBSA update, scheduled review date changed. Policy statement adds obesity as investigational.</td>
</tr>
<tr>
<td>06/16/05</td>
<td>Device name change added - Reference to Enterra added to Gastric Electrical Stimulation System for clarification purposes only. MPC approval not needed.</td>
</tr>
<tr>
<td>01/10/06</td>
<td>Replace Policy - Policy reviewed with literature search; codes updated; policy statement unchanged.</td>
</tr>
<tr>
<td>02/06/06</td>
<td>Codes updated - No other changes.</td>
</tr>
<tr>
<td>06/06/09</td>
<td>Disclaimer and Scope update - No other changes.</td>
</tr>
<tr>
<td>09/18/06</td>
<td>Codes Updated - No other changes.</td>
</tr>
<tr>
<td>01/09/06</td>
<td>Replace Policy - Policy updated with literature review. No change in policy statement. Codes updated.</td>
</tr>
<tr>
<td>02/26/07</td>
<td>Codes Updated - No other changes.</td>
</tr>
<tr>
<td>04/02/07</td>
<td>Codes Updated - No other changes.</td>
</tr>
<tr>
<td>01/08/08</td>
<td>Replace Policy - Policy updated with literature review; no change to the policy statement.</td>
</tr>
<tr>
<td>01/13/09</td>
<td>Code Updates - Code S2213 deleted</td>
</tr>
<tr>
<td>09/15/09</td>
<td>Replace Policy - Policy updated with literature review; no change to the policy statement. References added.</td>
</tr>
<tr>
<td>02/09/10</td>
<td>Code Update - New 2010 codes added.</td>
</tr>
<tr>
<td>11/09/10</td>
<td>Replace Policy - Policy updated with literature review; no change to the policy statement. Reference added.</td>
</tr>
<tr>
<td>09/15/11</td>
<td>Replace Policy – Policy updated with literature review; no change in policy statement.</td>
</tr>
<tr>
<td>08/20/12</td>
<td>Replace Policy. Policy updated with literature review, references 21 and 22 added; no change in policy statement.</td>
</tr>
<tr>
<td>10/09/12</td>
<td>Update Related Policies – Add 8.03.01.</td>
</tr>
<tr>
<td>02/04/13</td>
<td>Code update. HCPCS code E0765 added to the policy.</td>
</tr>
<tr>
<td>02/12/13</td>
<td>Update Related Policies, add 1.01.507.</td>
</tr>
<tr>
<td>10/14/13</td>
<td>Replace policy. Policy updated with extensive literature revision. No change in policy statement. CPT codes 0155T, 0156T, 0157T and 0158T removed from policy; they were deleted effective 1/2012.</td>
</tr>
<tr>
<td>12/03/13</td>
<td>Coding Update. Add ICD-10 codes.</td>
</tr>
</tbody>
</table>
| 11/20/14   | Annual Review. Policy updated with literature review. Policy statement remains unchanged. References 23, 26 and 27 added. All CPT codes removed except 43647,
<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>02/25/15</td>
<td>Interim Update. Adding FDA Approved device. Related policy 7.01.20 added.</td>
</tr>
<tr>
<td>09/01/15</td>
<td>Update Related Policies. Add 7.01.150.</td>
</tr>
<tr>
<td>01/10/17</td>
<td>Interim review. Coding update; added CPT code 95980. Combined coding tables.</td>
</tr>
<tr>
<td>05/01/17</td>
<td>Annual review, changes approved April 11, 2017. Policy updated with literature review through December 22, 2016; reference 1 added. Policy statements unchanged.</td>
</tr>
<tr>
<td>08/25/17</td>
<td>Coding update, removed CPT code 95980. Supporting information added to Summary of Evidence section. Policy moved into new format; no change to policy statements.</td>
</tr>
<tr>
<td>05/01/18</td>
<td>Annual Review, approved April 3, 2018. Policy updated with literature review through December 2017; 1 reference added. Policy statements unchanged.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2018 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination is Against the Law

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:
- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-4535, Fax 425-918-5952. TTY 800-842-5357
Email AppealsDepartmentInquiries@Premera.com

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at:
https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:
U.S. Department of Health and Human Services
200 Independence Avenue SW, Room S09F, HHH Building
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)
Complaint forms are available at:

Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call 800-722-1471 (TTY: 800-842-5357).

Oromo (Cushite):

Français (French):

Deutsche (German):

Ilokano (Ilocano):
Daytoy a Pakdaar ket naglaon iti Napateg nga Impormasion. Daytoy a pakdaar mabalini nga adda ket naglaon iti napateg nga impormasion maiyanggep iti aplikasyonyo wenno coverage babaen iti Premera Blue Cross. Daytoy ket mabalini dagiti importante a petsa iti daytoy a pakdaar. Mabalini nga adda rumbeng nga aramidenyo nga addang sakbay dagiti partikular a naituding nga aldaw tiin tajaajila keessan ilaalchise. Guyyaawwan muureessaa ta’an deeggarammuuf yoo kan tajaali fayyaa keessaniiif guyyaaw dhumaan irratii wanti raawu watti jiraachu danda’a. Kaffaltii irraa bilisa haala ta’een afan keessanin oodefannoo argachuu fi deeggarsa arguchuu minga ni qabattuu. Lakkofisa bibibila 800-722-1471 (TTY: 800-842-5357) ti bibibila.

Italiano (Italian):
Premera Blue Cross sends you this message in order to help you understand the coverage terms and conditions that may be contained in your health plan's benefit document. Review the information, and if you have questions, please contact Premera Blue Cross at 800-722-1471 (TTY: 800-842-5357) to obtain assistance.

العربية (Arabic): 
لا يمكن للمواطنين القادة من تقديم معلومات عن أجهزة الرعاية الصحية أو المساعدات المهنية للمعلومات المقدمة في هذه الرسالة. يرجى مراجعة المعلومات المقدمة، وإذا تصحح، يرجى الاتصال بشركة Premera Blue Cross على الرقم 800-722-1471 (TTY: 800-842-5357) للحصول على المساعدة.

الإسبانية (Spanish): 
Premera Blue Cross le envía este mensaje con el fin de ayudarlo a entender las condiciones y términos de la cobertura que puedan incluirse en su documento de plan de beneficios. Revise la información, y si tiene alguna pregunta, comuníquese con Premera Blue Cross llamando al 800-722-1471 (TTY: 800-842-5357) para obtener asistencia.

الفرنسية (French): 
Premera Blue Cross vous avise de certaines conditions d’assurance et vous demande de vérifier la précision des informations fournies dans cette communication. Si vous avez des questions, n’hésitez pas à faire un appel sans frais au 800-722-1471 (TTY: 800-842-5357) pour obtenir de l’aide.

الرومانية (Romanian): 

العربية (Arabic): 
لا يمكن للمواطنين القادة من تقديم معلومات عن أجهزة الرعاية الصحية أو المساعدات المهنية للمعلومات المقدمة في هذه الرسالة. يرجى مراجعة المعلومات المقدمة، وإذا تصحح، يرجى الاتصال بشركة Premera Blue Cross على الرقم 800-722-1471 (TTY: 800-842-5357) للحصول على المساعدة.

الإسبانية (Spanish): 
Premera Blue Cross le envía este mensaje con el fin de ayudarlo a entender las condiciones y términos de la cobertura que puedan incluirse en su documento de plan de beneficios. Revise la información, y si tiene alguna pregunta, comuníquese con Premera Blue Cross llamando al 800-722-1471 (TTY: 800-842-5357) para obtener asistencia.

الفرنسية (French): 
Premera Blue Cross vous avise de certaines conditions d’assurance et vous demande de vérifier la précision des informations fournies dans cette communication. Si vous avez des questions, n’hésitez pas à faire un appel sans frais au 800-722-1471 (TTY: 800-842-5357) pour obtenir de l’aide.

الرومانية (Romanian): 